Last updated: February 13, 2026
Overview
NDC 24979-0109 corresponds to Tafasitamab (development code: MOR208), marketed as Monjuvi by MorphoSys and Incyte. It is a monoclonal antibody targeting CD19, approved by the FDA in August 2020 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide. The drug's market is evolving with significant competition and emerging indications.
Market Position and Indications
- Approved Indication: Treatment of adult patients with relapsed or refractory DLBCL who are ineligible for autologous stem cell transplant.
- Additional Sales Drivers: Ongoing trials expanding indications into other B-cell malignancies and potential combination therapies.
- Market Size: Estimated to be approximately 25,000 new cases annually in the U.S. for DLBCL, with about 30-40% eligible for Monjuvi based on clinical criteria.
Current Market Dynamics
- Competitive Landscape: Monjuvi competes primarily with CAR-T therapies like axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi). These therapies are more expensive but offer potentially curative outcomes.
- Pricing Strategy: Monjuvi is priced at approximately $11,000 per infusion (including the drug and administration), with an average treatment course comprising 2-4 doses, leading to a treatment cost around $22,000–$44,000 per patient.
- Reimbursement: Covered by Medicare and commercial payers, with strong indications for use in specific patient populations.
Price Projections (2023–2028)
| Year |
Estimated Average Treatment Cost per Patient |
Rationale |
| 2023 |
$22,000 – $44,000 |
Current pricing, steady reimbursement, market acceptance. |
| 2024 |
$23,100 – $45,200 |
Slight price increase (approx. 5%), volume growth begins. |
| 2025 |
$24,255 – $47,460 |
Modest inflation, expanded label indications, increased adoption. |
| 2026 |
$25,467 – $49,733 |
New combination therapies introduced, potential price adjustments. |
| 2027 |
$26,735 – $52,119 |
Market maturation, competition from biosimilars unlikely initially. |
| 2028 |
$28,071 – $54,725 |
Continued inflation, new clinical data supporting use will expand market share. |
Volume and Revenue Outlook
- 2023: Approx. 2,000–3,000 treated patients in the U.S., generating revenues of ~$44–$132 million.
- 2024–2028: Growth driven by increased diagnosis rates, expanding indications, and combination strategies. Potentially reaching 5,000–8,000 treated patients annually by 2028, translating into revenues of $220–$440 million.
Key Factors Influencing Price and Market
- Regulatory Developments: Additional approvals or expanded indications may increase demand.
- Competitive Pressures: Appearance of biosimilars and newer therapies could pressure pricing.
- Reimbursement Policies: Changes could affect net pricing.
Risks to Price Projections
- Introduction of biosimilars or generics could reduce prices by 20–40%.
- Displacement by CAR-T therapies or novel agents for DLBCL.
- Market penetration limits due to clinical positioning or safety concerns.
Summary
Monjuvi maintains a niche within B-cell lymphoma treatment, with stable pricing affected by market dynamics, competition, and clinical adoption. Price growth remains modest, with revenue expansion driven primarily by increased treatment volume and broader indications.
Key Takeaways
- Monjuvi (NDC 24979-0109) is positioned as a targeted therapy for relapsed/refractory DLBCL with an estimated treatment cost of $22,000–$44,000 per course.
- Sales growth depends on expanding indications, market acceptance, and competition. Expect annual revenue growth of approximately 10% until 2028.
- Market risks include biosimilar entry and competitive treatment options such as CAR-T therapies.
- Price adjustments are modest, reflecting current market and reimbursement realities.
- The drug’s commercial success hinges on clinical adoption and payer coverage policies.
FAQs
1. What is the current price of Monjuvi treatment per patient?
Approximately $22,000 to $44,000 for a full course, depending on dosing and treatment duration.
2. How does Monjuvi compare to CAR-T therapies?
Monjuvi is generally less expensive but offers different efficacy outcomes and treatment paradigms. CAR-T therapies are often used after Monjuvi failure due to their higher costs and curative potential.
3. Are biosimilars expected for Monjuvi?
Biosimilars for monoclonal antibodies are evolving; no biosimikars are commercially available yet for Monjuvi. Entry could be anticipated within 5–7 years depending on patents and market response.
4. What factors could influence future prices?
Regulatory changes, market competition, clinical data, and payer negotiations.
5. What is the expected market size for Monjuvi in the next five years?
Between 5,000 and 8,000 treated patients annually in the U.S., with growth driven by label expansion and increased clinical adoption.
Sources:
[1] FDA approval announcement for Monjuvi (August 19, 2020).
[2] Industry pricing reports (IQVIA, 2022).
[3] Market research on B-cell lymphoma treatments.
[4] Competitive analysis of CAR-T therapies.
